Evidence map›Paper›PMID 26692290›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2016

Response of esophageal cancer cells to epigenetic inhibitors is mediated via altered thioredoxin activity.

Theresa D Ahrens, Sylvia Timme, Jenny Ostendorp, Lioudmilla Bogatyreva, Jens Hoeppner, Ulrich T Hopt, Dieter Hauschke, Martin Werner, Silke Lassmann

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. NewInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. The production of 3D tumor spheroids for cancer drug discovery.Drug discovery today. Technologies · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Theresa D AhrensDepartment of Pathology, Institute of Surgical Pathology, University Medical Center, Freiburg, Germany.
Sylvia TimmeDepartment of Pathology, Institute of Surgical Pathology, University Medical Center, Freiburg, Germany.
Jenny OstendorpDepartment of Pathology, Institute of Surgical Pathology, University Medical Center, Freiburg, Germany.
Lioudmilla BogatyrevaInstitute of Biometry and Statistics, University Medical Center, Freiburg, Germany.
Jens HoeppnerDepartment of General and Visceral Surgery, University Medical Center, Freiburg, Germany.
Ulrich T HoptDepartment of General and Visceral Surgery, University Medical Center, Freiburg, Germany.
Dieter HauschkeInstitute of Biometry and Statistics, University Medical Center, Freiburg, Germany.
Martin WernerDepartment of Pathology, Institute of Surgical Pathology, University Medical Center, Freiburg, Germany.
Silke LassmannDepartment of Pathology, Institute of Surgical Pathology, University Medical Center, Freiburg, Germany.
University Medical Center Freiburg · DEUniversity of Freiburg · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously showed that histone deacetylase inhibitor (HDACi) and 5-azacytidine (AZA) treatment selectively induced cell death of esophageal cancer cells. The mechanisms of cancer selectivity, however, remained unclear. Here we examined whether the cancer selectivity of HDACi/AZA treatment is mediated by the thioredoxin (Trx) system and reactive oxygen species (ROS) in esophageal cancer cells. For this, we first analyzed human tissue specimens of 37 esophageal cancer patients by immunohistochemistry for Trx, Trx-interacting protein (TXNIP) and Trx reductase (TXNRD). This revealed a loss or at least reduction of nuclear Trx in esophageal cancer cells, compared with normal epithelial cells (P<0.001). Although no differences were observed for TXNIP, TXNRD was more frequently expressed in cancer cells (P<0.001). In the two main histotypes of esophageal squamous cell carcinomas (ESCCs, n=19) and esophageal adenomcarcinomas (EAC, n=16), similar Trx, TXNIP and TXNRD expression patterns were observed. Also in vitro, nuclear Trx was only detectable in non-neoplastic Het-1A cells, but not in OE21/ESCC or OE33/EAC cell lines. Moreover, the two cancer cell lines showed an increased Trx activity, being significant for OE21 (P=0.0237). After treatment with HDACi and/or AZA, ROS were exclusively increased in both cancer cell lines (P=0.048-0.017), with parallel decrease of Trx activity. This was variably accompanied by increased TXNIP levels upon AZA, MS-275 or MS-275/AZA treatment for 6 or 24 h in OE21, but not in Het-1A or OE33 cells. In summary, this study evaluated Trx and its associated proteins TXNIP and TXNRD for the first time in esophageal cancers. The analyses revealed an altered subcellular localization of Trx and strong upregulation of TXNRD in esophageal cancer cells. Moreover, HDACi and AZA disrupted Trx function and induced accumulation of ROS with subsequent apoptosis in esophageal cancer cells exclusively. Trx function is hence an important cellular mediator conferring non-neoplastic cell resistance for HDACi and/or AZA.

Indexed as

AdultAgedAged, 80 and overAzacitidineCarrier ProteinsCell Line, TumorEpigenesis, GeneticEsophageal NeoplasmsFemaleHistone Deacetylase InhibitorsHumansMaleMiddle AgedReactive Oxygen SpeciesThioredoxin Reductase 1ThioredoxinsAzacitidineCarrier ProteinsHistone Deacetylase InhibitorsReactive Oxygen SpeciesThioredoxin Reductase 1ThioredoxinsTXNIP protein, humanTXN protein, humanTXNRD1 protein, human

Identifiers

PMID26692290
OpenAlexW2212002366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.